Details of the Drug Combination

General Information of Drug Combination (ID: DC4QF8Q)

Drug Combination Name
Amonafide Uracil mustard
Indication
Disease Entry Status REF
Invasive ductal carcinoma Investigative [1]
Component Drugs Amonafide   DMAH59S Uracil mustard   DMHL7OB
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HS 578T
Zero Interaction Potency (ZIP) Score: 4.41
Bliss Independence Score: 6.48
Loewe Additivity Score: 1.67
LHighest Single Agent (HSA) Score: 9.74

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Amonafide
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [2]
Ovarian cancer 2C73 Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [2]
Indication(s) of Uracil mustard
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [3]
Chronic myelogenous leukaemia 2A20.0 Approved [4]
Polycythemia vera 2A20.4 Approved [4]
Small lymphocytic lymphoma 2A82.0 Approved [4]
Uracil mustard Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------
Uracil mustard Interacts with 5 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1) OT7FBG5W NAR1_HUMAN Increases ADR [6]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases ADR [6]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Increases ADR [6]
Poly polymerase 1 (PARP1) OTIESHK4 PARP1_ARATH Increases ADR [6]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases ADR [6]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DC6SA21 OVCAR3 Investigative [7]
Adult acute myeloid leukemia DCUF41O HL-60(TB) Investigative [7]
Anaplastic large cell lymphoma DC8LWD8 SR Investigative [7]
Astrocytoma DCVUYYC SNB-19 Investigative [7]
Clear cell renal cell carcinoma DCMI4OD 786-0 Investigative [7]
Clear cell renal cell carcinoma DCHB574 CAKI-1 Investigative [7]
Glioblastoma DCM681M SNB-75 Investigative [7]
Glioma DCDOFHS SF-268 Investigative [7]
Glioma DCG8T8J SF-295 Investigative [7]
High grade ovarian serous adenocarcinoma DCHY6KH OVCAR-4 Investigative [7]
High grade ovarian serous adenocarcinoma DCS32UT NCI\\/ADR-RES Investigative [7]
Large cell lung carcinoma DCMEXZP NCI-H460 Investigative [7]
Lung adenocarcinoma DC2YSTF HOP-62 Investigative [7]
Malignant melanoma DCXPP7O LOX IMVI Investigative [7]
Melanoma DCS7NVV SK-MEL-2 Investigative [7]
Minimally invasive lung adenocarcinoma DCQHAWJ NCI-H322M Investigative [7]
Non-small cell lung carcinoma DCZ3N1U HOP-92 Investigative [7]
Papillary renal cell carcinoma DCDFJ89 ACHN Investigative [7]
Prostate carcinoma DCMX3US PC-3 Investigative [7]
Colon adenocarcinoma DC2OJOQ COLO 205 Investigative [1]
Colon carcinoma DCYEYNI KM12 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 21 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7621).
4 Uracil mustard FDA Label
5 Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8.
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.